Isoandrografolide analogs and therapeutic methods using them
Isoandrografolide analogs targeting specific therapeutic pathways effectively treat fibrosis and atopic dermatitis by modulating neutrophil migration and associated pathways, addressing the inadequacies of current treatments.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- エンヴェダ セラピューティクス インコーポレイテッド
- Filing Date
- 2024-05-17
- Publication Date
- 2026-06-26
AI Technical Summary
Current treatments for fibrosis and atopic dermatitis are inadequate, and there is a need for compounds and methods to address fibrosis-related diseases and conditions, as well as conditions related to neutrophil migration, which affect a significant portion of the global population and pose a substantial public health burden.
Development of isoandrografolide analogs, specifically compounds of formulas (I) and (II), which act as inhibitors or modulators of therapeutic targets such as neutrophil migration, cathepsin D, surfactant protein C, glutathione, type I collagen α1, pyruvate carboxylase, 90kD heat shock protein, and transforming growth factor β, to treat or prevent fibrosis and atopic dermatitis, among other diseases.
The compounds effectively reduce symptoms of fibrosis and atopic dermatitis by modulating neutrophil migration and associated pathways, demonstrating therapeutic potential across various disease models, including pulmonary fibrosis, atopic dermatitis, and other inflammatory conditions.
Smart Images
Figure 2026521119000001_ABST